TP53 and ovarian cancer: Various copper-based compounds have been tested on colon, breast, prostate, and ovarian cancer cells, demonstrating their ability to induce the activity of pro-apoptotic molecules such as p53, BAX, caspase-8 and -9, while inhibiting the expression of Bcl-2.